Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Said Farschtschi

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Deutsches Arzteblatt International|March 24, 2021
In ReplySaid Farschtschi
Neurogenetics|April 27, 2026
Divergence in intra-tumor variant frequencies in sporadic vestibular schwannomas as a potential indication for mosaic NF2-related schwannomatosis?Lan Kluwe, Tabea Hartung, Steffen Rosahl, et al.
Human Genetics|December 7, 2016
The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesisHildegard Kehrer-Sawatzki, Said Farschtschi, Victor-Felix Mautner, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|March 22, 2015
Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2Said Farschtschi, Philipp Kollmann, Carsten Dalchow, et al.
Deutsches Arzteblatt International|January 8, 2025
Age-Adapted Diagnostic Evaluation and Treatment of Patients With Type 1 Neurofibromatosis in GermanySaid Farschtschi, Pia Vaassen, Lan Kluwe, et al.
Muscle & Nerve|July 17, 2016
Muscle action potential scans and ultrasound imaging in neurofibromatosis type 2Said Farschtschi, Mathias Gelderblom, Sabriena Buschbaum, et al.
Orphanet Journal of Rare Diseases|January 6, 2025
Clinical severity grading of NF2-related schwannomatosisAnna C Lawson McLean, Denise Löschner, Said Farschtschi, et al.
Experimental Neurology|June 8, 2017
Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunitiesAlexander Schulz, Peter Grafe, Christian Hagel, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|June 14, 2020
Clinical characterization of children and adolescents with NF1 microdeletionsHildegard Kehrer-Sawatzki, Lan Kluwe, Johannes Salamon, et al.
Orphanet Journal of Rare Diseases|November 4, 2024
Whole-body MRI-based long-term evaluation of pediatric NF1 patients without initial tumor burden with evidence of newly developed peripheral nerve sheath tumorsMarie-Lena Schmalhofer, Said Farschtschi, Lan Kluwe, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Deutsches Arzteblatt International|March 24, 2021
In ReplySaid Farschtschi
Neurogenetics|April 27, 2026
Divergence in intra-tumor variant frequencies in sporadic vestibular schwannomas as a potential indication for mosaic NF2-related schwannomatosis?Lan Kluwe, Tabea Hartung, Steffen Rosahl, et al.
Human Genetics|December 7, 2016
The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesisHildegard Kehrer-Sawatzki, Said Farschtschi, Victor-Felix Mautner, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|March 22, 2015
Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2Said Farschtschi, Philipp Kollmann, Carsten Dalchow, et al.
Deutsches Arzteblatt International|January 8, 2025
Age-Adapted Diagnostic Evaluation and Treatment of Patients With Type 1 Neurofibromatosis in GermanySaid Farschtschi, Pia Vaassen, Lan Kluwe, et al.
Muscle & Nerve|July 17, 2016
Muscle action potential scans and ultrasound imaging in neurofibromatosis type 2Said Farschtschi, Mathias Gelderblom, Sabriena Buschbaum, et al.
Orphanet Journal of Rare Diseases|January 6, 2025
Clinical severity grading of NF2-related schwannomatosisAnna C Lawson McLean, Denise Löschner, Said Farschtschi, et al.
Experimental Neurology|June 8, 2017
Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunitiesAlexander Schulz, Peter Grafe, Christian Hagel, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|June 14, 2020
Clinical characterization of children and adolescents with NF1 microdeletionsHildegard Kehrer-Sawatzki, Lan Kluwe, Johannes Salamon, et al.
Orphanet Journal of Rare Diseases|November 4, 2024
Whole-body MRI-based long-term evaluation of pediatric NF1 patients without initial tumor burden with evidence of newly developed peripheral nerve sheath tumorsMarie-Lena Schmalhofer, Said Farschtschi, Lan Kluwe, et al.
Pageof 5